BioCentury
ARTICLE | Clinical News

FDA reviewing Sun's psoriasis candidate tildrakizumab

June 1, 2017 9:00 PM UTC

Sun Pharmaceutical Industries Ltd. (BSE:524715; NSE:SUNPHARMA) said FDA accepted for review a BLA for tildrakizumab (MK-3222) to treat moderate to severe plaque psoriasis. The company declined to disclose the PDUFA date.

In March, EMA validated an MAA for the product in the indication (see BioCentury, April 3)...